ES2551736T3 - Anticuerpos anti-hedgehog - Google Patents

Anticuerpos anti-hedgehog Download PDF

Info

Publication number
ES2551736T3
ES2551736T3 ES08867163.1T ES08867163T ES2551736T3 ES 2551736 T3 ES2551736 T3 ES 2551736T3 ES 08867163 T ES08867163 T ES 08867163T ES 2551736 T3 ES2551736 T3 ES 2551736T3
Authority
ES
Spain
Prior art keywords
hedgehog
tissue
antibody
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08867163.1T
Other languages
English (en)
Spanish (es)
Inventor
Suzanna J. Scales
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2551736T3 publication Critical patent/ES2551736T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES08867163.1T 2007-12-28 2008-12-22 Anticuerpos anti-hedgehog Active ES2551736T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17232P 1996-05-09
US99864P 1998-09-11
US1723207P 2007-12-28 2007-12-28
US9986408P 2008-09-24 2008-09-24
PCT/US2008/088059 WO2009086324A1 (en) 2007-12-28 2008-12-22 Anti-hedgehog antibodies

Publications (1)

Publication Number Publication Date
ES2551736T3 true ES2551736T3 (es) 2015-11-23

Family

ID=40433914

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08867163.1T Active ES2551736T3 (es) 2007-12-28 2008-12-22 Anticuerpos anti-hedgehog

Country Status (7)

Country Link
US (3) US8030454B2 (enExample)
EP (1) EP2235063B1 (enExample)
JP (1) JP5715420B2 (enExample)
AU (1) AU2008345246B2 (enExample)
CA (1) CA2709399C (enExample)
ES (1) ES2551736T3 (enExample)
WO (1) WO2009086324A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
PH12022550313A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
US11867696B2 (en) * 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
CN104645358A (zh) * 2015-02-09 2015-05-27 中国人民解放军第二军医大学 一种胰腺癌靶向的纳米级超声造影剂及其制备方法和应用
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN112805299B (zh) 2018-10-05 2025-09-16 西雅图儿童医院以西雅图儿童研究机构名义经营 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US7060450B1 (en) * 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
AU767066B2 (en) * 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
IL153115A0 (en) * 2000-06-16 2003-06-24 Curis Inc Angiogenesis-modulating compositions and uses
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CA2425356C (en) * 2000-10-13 2015-10-06 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
ES2707393T3 (es) * 2004-03-26 2019-04-03 Curis Inc Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos

Also Published As

Publication number Publication date
EP2235063A1 (en) 2010-10-06
AU2008345246A1 (en) 2009-07-09
EP2235063B1 (en) 2015-09-02
CA2709399C (en) 2021-01-19
AU2008345246B2 (en) 2014-08-07
US8030454B2 (en) 2011-10-04
CA2709399A1 (en) 2009-07-09
US20130011853A1 (en) 2013-01-10
US20100003239A1 (en) 2010-01-07
JP2011511762A (ja) 2011-04-14
US20120028829A1 (en) 2012-02-02
JP5715420B2 (ja) 2015-05-07
HK1146595A1 (zh) 2011-06-24
WO2009086324A1 (en) 2009-07-09
US8338112B1 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
ES2551736T3 (es) Anticuerpos anti-hedgehog
ES2753360T3 (es) Anticuerpos contra PD-L1 y usos de los mismos
ES2372321T3 (es) Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
ES2377885T3 (es) Uso de antagonistas de hedgehog cinasa para inhibir la señalización de hedgehog y para tratar cáncer
JP2010511056A (ja) Ｉｌ−１７ａ／ｆヘテロ二量体ポリペプチドおよびその治療上の使用
ES2316175T3 (es) Antigenos especificos de plaquetas y sus usos farmacologicos.
US8435754B2 (en) Method of diagnosing the presence of a tumor in a mammal by assessing CDO expression levels
KR101771714B1 (ko) 변이체 ｈｈｉｐ1 단백질 및 방법 및 그의 용도
US20220363738A1 (en) Method
ES2369383T3 (es) Método auxiliar para diagnosis y terapia de cáncer con nucleolina.
ES2625259T3 (es) Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
ES2396672T3 (es) Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata
HK1146595B (en) Anti-hedgehog antibodies
AU2007243946B2 (en) Method for using BOC/CDO to modulate hedgehog signaling
ES2311039T3 (es) Proteina de tipo antigeno de a33 humano y acidos nucleicos que la codifican.
CN119487064A (zh) 针对Tie-2和VEGF的抗体及使用方法
KR20120140097A (ko) 암 진단 및 치료용 조성물 및 방법
AU2013204025A1 (en) Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders